Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer

Official Title

A Randomized, Multicentre, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer


A randomized multi-arm study evaluating the safety and efficacy of nivolumab versus placebo in combination with paclitaxel in participants with ER+/HER2- breast cancer

Trial Description

Primary Outcome:

  • Pathological Complete response (pCR) Pathological Complete response (pCR) Using the definition of ypT0/Tis ypN0
  • Event-Free Survival (EFS)
Secondary Outcome:
  • Overall Survival (OS)
  • Disease-free Survival (DFS)
  • Distant Metastasis-free survival (DMFS)
  • Pathological Complete Response (pCR) using the definition of ypT0ypN0
  • Pathological Complete Response (pCR) rate using the definition of ypT0/is
  • Objective Response Rate (ORR)
  • Breast Conserving Surgery (BCS) rate
  • Number of participants experiencing an adverse event (AE)
  • Change from baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Score (EORTC QLQ-C30) global health status/quality of life (QOL) subscale (items 29 and 30)
  • Change from baseline on the EORTC QLQ-C30 physical functioning subscale (items 1 to 5)

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society